
Opinion|Videos|November 20, 2025
Improving Adherence and Transitioning to SC Therapy
Panelists discuss how SC formulations enhance adherence through simpler, patient-friendly treatment delivery.
Advertisement
Episodes in this series

Panelists discuss how subcutaneous (SC) therapy can improve adherence by minimizing treatment disruptions and simplifying logistics. They explore best practices for transitioning patients from intravenous (IV) to SC formulations, emphasizing the importance of education, monitoring, and gradual integration. The conversation underscores that streamlined delivery and patient familiarity promote long-term adherence and confidence in SC therapy as an equivalent yet more convenient alternative to IV treatment.
Advertisement
Related to this article

The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.

A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.

Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.

SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT
2
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
3
Data Show Upadacitinib Repigments Skin in Nonsegmental Vitiligo
4
Oral Iberdomide May Widen Myeloma Access: Mateo Mejia Saldarriaga, MD
5

